Munich, Germany: A strategy of alternately flooding and starving the body of testosterone is producing good results in patients who have metastatic prostate cancer that is resistant to treatment by chemical or surgical castration, ...
Nov 30, 2016
0
14
A database study examining surgical removal of the prostate gland (radical prostatectomy) or a form of radiation therapy known as IMRT to treat prostate cancer that has spread to other parts of the body (metastatic) shows ...
Sep 26, 2016
0
0
Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of defense, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy ...
Jun 15, 2016
0
3
Conventional imaging methods have limited sensitivity for detecting metastatic prostate cancer. With appropriate, timely treatment vital to survival and quality of life, better imaging has been an ongoing goal.
Jan 27, 2016
0
33
A novel molecular imaging technology not only detects prostate cancer that has spread throughout the body, but also provides a potent and minimally invasive method of radiotherapy, reveal researchers at the 2015 Society of ...
Jun 8, 2015
0
7
A novel radionuclide drug tackles the challenge of prostate cancer imaging and takes a turn as a cancer-killing therapy for tumors in and out of the prostate, according to research presented during the 2015 Annual Meeting ...
Jun 8, 2015
0
212
Enzalutamide (trade name: Xtandi) has been approved since December 2014 for men who have metastatic prostate cancer that is not susceptible to hormone-blocking therapy, who have no symptoms or only mild ones, and in whom ...
Apr 10, 2015
0
7
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the ...
Mar 20, 2015
0
5
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. The German Institute for Quality and Efficiency ...
Jan 8, 2015
0
21
Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to ...
Jun 2, 2014
0
0
